Accredited clinical laboratory and life sciences company

2010

Lung Cancer: New Insights for the Healthcare Professional: 2011 Edition


Lung Cancer - Researchers at Genomac International target lung cancer. Report, "A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and IYILPA; is newly published data in Electrophoresis. 'There is a growing interest in evaluating molecular markers as predictors of response to new generation of targeted cancer therapies. One or such areas is biological therapy targeting epidermal growth factor receptor gene (EGFR) in lung cancer," scientists in Prague, Czech Republic report. The testing of tumor tissue is focused on specific EGFR mutations and EGFR gene amplification, since tumors exhibiting positivity of either of the two marker types are highly sensitive towards the treatment. Although traditional methods of DNA sequencing and fluorescence in situ hybridization are still in use for the detection of EGFR mutations and gene amphfication, respectively, there is a need for new dedicated techniques with the primary. emphasis on simplicity, sensitivity, speed and cost effectiveness_ The main purpose of this work was to integrate diverse assays for both EGFR tests onto a single platform to eliminate the need for different instruments and separate processing. We demonstrate a chip capillary electrophoresis (chipCE) application for EGFR mutation detection by a combination of fragment analysis and denaturing CE. along with multiplex ligation-dependent probe amplification (MLPA) for evaluation of EGFR amplification. All separations are carried out in denaturing sieving polymer on a modified Bioanalyzer 2100 chi peE instrument running at temperatures of up to 65&.# I 76;C. The main strength of the resulting high-resolution chipCE application is in its simplicity, speed of analysis and minimal amount of sample required for complete testing of EGFR status: wrote M. Minarik and colleagues. Genomac International. The researchers concluded: 'Such an approach could potentially fit medium throughput laboratories providing molecular pathology services for clinical oncologists with fast turnaround times and limited consumption of tissue material." Mina.rik and colleagues published their study in Elearophoresjs (A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA. Electrophoresis, .201 031(2.1):3518-24). (2010-12-14)


For more information, contact M. Minarik, Laboratory for Molecular Genetics and Oncology, Genomac International, Prague, Czech Republic. (2010 DEC 14)

 

 


Biotech Week: Researchers from Genomac International publish findings in non-small cell lung cancer


A new study, 'Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors,' is now available. According to recent research from Prague, Czech Republic, "Concurrent presence of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients is relatively rare and their appearance is believed to be mutually exclusive. Tumours harbouring KRAS mutation are perceived as not being capable of response to tyrosine kinase inhibitor (TKI) therapy." Link: http://www.highbeam.com/doc/1G1-231871710.html (2010-07-21)